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144 but were not associated with HBV DNA rebound; in vitro phenotypic
analysis of these mutations is ongoing.
Conclusion: ADV resistance mutations (rtN236T and rtA181V) emerged
at a delayed rate and with a low frequency (cumulative probability of 3.9%)
after 144 weeks of therapy in all patients in this analysis.
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Hepatitis C Virus (HCV) translation and replication is supported by several
cellular RNA binding proteins. Polypyrimidine tract-binding protein (PTB)
has previously been shown to stimulate HCV IRES-mediated translation by
binding to the HCV 3′ untranslated region (3′UTR). Hu antigen R (HuR)
binds to A+U rich regions and protects mRNA against degradation. Mod-
ulation of the HCV IRES activity by proteasome a-subunit PSMA7 has
been shown previously. RNA interference for destruction of these genes
might substantially inhibit HCV replication and translation. The aim of
our study was to examine the effects of siRNA-mediated inhibition of cel-
lular RNA binding proteins on HCV IRES-mediated translation and HCV
subgenomic replication. A panel of siRNA molecules directed against PTB,
HuR and PSMA7 were expressed from a U6-promoter within a retroviral
vector construct. SiRNA plasmids were cotransfected with a bicistronic re-
porter construct (Renilla-HCV IRES-Firefly-poly(U/C) tract-3′UTR) into
Huh7 cells. Compared with a control siRNA, a reduction in luciferase ac-
tivity of up to 40% was observed for selected siRNAs. SiRNA expression
plasmids were transfected in HuH7 cells expressing monocistronic subge-
nomic HCV replicon. Northern blot analysis revealed reduction of up to
60% in HCV replicon RNA by siRNAs targeting HuR and PSMA7 RNA.
In contrast, siRNAs targeting PTB mRNA revealed no significant effects.
PSMA7- and HuR-directed siRNAs reduced HCV NS5B protein levels
in Western blotting analyses up to 40%. These results demonstrate that
HCV IRES-mediated translation and HCV subgenomic replication can be
inhibited by depletion of HCV cofactors, especially PSMA7 and HuR.
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We have used a structure-based approach to design small molecule in-
hibitors of the HCV NS34A protease as potential candidates for new, more
effective anti-HCV therapies. VX-950 was recently selected as a clinical
development candidate for treatment of Hepatitis C infection. In this report,
we describe in vitro resistance studies on VX-950 and BILN-2061, another
HCV protease inhibitor from Boehringer Ingelheim, using a sub-genomic
replicon system. Distinct drug-resistant mutations were identified for both
HCV serine protease inhibitors. The major BILN-2061-resistant mutations
remain fully susceptible to VX-950, and the primary resistance mutation
against VX-950 remains sensitive to BILN-2061. Our structural analysis
suggests that resistance develops in response to VX-950 and BILN 2061
via different mechanisms. Cross-resistance mutations were identified under
selection with both HCV protease inhibitors. Characterization of the enzy-
matic and anti-viral properties of the mutations that confer cross-resistance
to both VX-950 and BILN-2061 will be presented.
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Background: Steatosis, the hallmark of Non Alcoholic Fatty Liver Disease
(NAFLD), is a common histological finding also in patients with chronic
HCV hepatitis, but the mechanism(s) of fat accumulation might be differ-
ent.
Aims: To compare insulin sensitivity, glucose and lipid metabolism in HCV
and NAFLD patients with similar degree of liver steatosis and fibrosis.
Methods: Insulin sensitivity, glucose and glycerol turnover were evalu-
ated by euglycemic clamp technique (insulin infusion rate:1 mU/kg·min)
combined with tracers infusion (2H2glucose and 2H5glycerol) in 4 lean,
non-diabetic HCV patients, 5 matched NAFLD patients and 4 healthy con-
trols.
Results: Insulin stimulated glucose disposal was markedly reduced in
NAFLD compared with HCV patients (M=2.96±1.62 mg/kg·min vs
6.10±1.80 mg/kg·min, P=0.017) and controls (M=7.91±0.34 mg/kg·min,
P=0,00001). Hepatic glucose production (HGP) was similar in the three
groups in the basal state, but less efficiently inhibited by insulin both
in HCV and NAFLD (HGP during clamp=0.31±0.36 and 0.29±0.15
mg/kg·min vs 0.09±0.03 in controls;P=0,06). In the basal state, glyc-
erol Ra was increased in NAFLD compared with both HCV and controls
(2.58±0.48 vs 1.77±0.76 and 1.50±0.23 respectively, P=0.05) and less
suppressed by insulin. The amount of hepatic steatosis was directly related
to basal glycerol turnover in NAFLD (r=0.63) and inversely in HCV (r=
-0.60).
Conclusions: Liver steatosis a)in NAFLD is associated with peripheral
insulin resistance and increased systemic lipolysis, b)in HCV with normal
peripheral insulin sensitivity and reduced lipid turnover. These findings
suggest that fat accumulation is secondary to increased lipid delivery to the
liver in NAFLD, to reduced lipid dismission from the liver in HCV.
